Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia

Leukemia. 2021 Feb;35(2):295-298. doi: 10.1038/s41375-020-01110-3. Epub 2020 Dec 16.

Roland B Walter^{1

2

3

4}, Frederick R Appelbaum^{5

6}, Elihu H Estey^{5

7}

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. rwalter@fredhutch.org.
² Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
⁴ Department of Epidemiology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁶ Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.
⁷ Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA.

No abstract available

MeSH terms